COMMUNIQUÉS West-GlobeNewswire

InterCure Announces Strategic Acquisition of ISHI, Unlocking Access to Premium U.S. Cannabis Technology and Brands
19/09/2025
Acquisition of leading cannabis company marks major milestone in InterCure’s commercial expansion strategy, bringing access to premium American brands and state-of-the-art cultivation technologies Transaction comes as [...]
MomentMD Expands Virtual Clinical Education Platform Amid Growing Provider Shortages and Clinical Rotation Crisis
19/09/2025
With new partnerships and technology updates, the first-of-its-kind platform offers graduate programs immediate solutions to placement bottlenecks MomentMD Logo FORT LAUDERDALE, Fla., Sept. 19, 2025 (GLOBE NEWSWIRE) -- [...]
CrazyBulk 2025 | D-BAL, Testo-max , Trenorol , Ultimate Stack Legal Steroids Alternatives launch BY CrazyBulk In USA.
19/09/2025
CrazyBulk introduce safe and effective formula as best Legal Steroids Alternatives for muscle building and bodybuilding without any side effects over the counter supplement new york, Sept. 19, 2025 (GLOBE NEWSWIRE) -- [...]
Signature HealthCARE Committed to Proactive Resident Safety with SafeSpace Global Corporation
19/09/2025
Knoxville, TN, Sept. 19, 2025 (GLOBE NEWSWIRE) -- SafeSpace Global Corporation (OTCID:SSGC), a global leader in multimodal AI technology, is pleased to announce an expanded partnership with Signature HealthCARE. [...]
The Ensign Group, Inc. Declares Quarterly Dividend of $0.0625 Per Share
19/09/2025
SAN JUAN CAPISTRANO, Calif., Sept. 19, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living [...]
Skye Presents Phase 1b Data for its Peripheral CB1-inhibiting Antibody, Nimacimab, at European Association for the Study of Diabetes (EASD) Annual Meeting
19/09/2025
Novel CB1 inhibitor Phase 1b data highlights lack of neuropsychiatric adverse events and favorable gastrointestinal tolerability SAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (“Skye [...]
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
19/09/2025
Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense , also known as Zaire ebolavirus Supply is being [...]
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia
19/09/2025
NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that the National Comprehensive [...]
80,802 Orion Corporation A shares converted into B shares
19/09/2025
ORION CORPORATION STOCK EXCHANGE RELEASE – OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 19 SEPTEMBER 2025 at 9.00 EEST 80,802 Orion Corporation A shares converted into B shares In accordance with [...]
Anteris Technologies Global Corp. Announces Adjournment of Special Meeting of Stockholders
19/09/2025
MINNEAPOLIS and BRISBANE, Australia, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. ( Anteris or the Company ) (NASDAQ: AVR , ASX: AVR), a global structural heart company committed to designing, [...]
Idorsia’s JERAYGO (aprocitentan) approved in Switzerland for the treatment of resistant hypertension
19/09/2025
Idorsia receives approval from Swissmedic for JERAYGO ™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension. JERAYGO is a new oral antihypertensive [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Pricing of $9 Million Public Offering
19/09/2025
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
18/09/2025
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on September 15, 2025 it granted stock options to purchase an aggregate of 39,790 shares of [...]
iCare ABA Therapy Launches With AI-Supported Model, Sparks Industry Debate on AI’s Role in Autism Care
18/09/2025
New York, NY, Sept. 18, 2025 (GLOBE NEWSWIRE) -- The soft launch of iCare ABA Therapy is drawing attention across healthcare, real estate, and investment circles for one reason: its deliberate investment in artificial [...]
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
18/09/2025
FOSTER CITY, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it has granted equity awards covering an aggregate of 966,000 [...]
Palisade Bio Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum
18/09/2025
Carlsbad, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade”, “Palisade Bio”, or the “Company”), a clinical-stage biopharmaceutical company advancing novel therapeutics for patients [...]
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
18/09/2025
CONSHOHOCKEN, Pa., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated [...]
Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
18/09/2025
SOUTH SAN FRANCISCO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative [...]
Reviva Pharmaceuticals Holdings, Inc. Announces Proposed Public Offering
18/09/2025
CUPERTINO, Calif., Sept. 18, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies that seek to address unmet [...]

Pages